Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteersFreiburg im Breisgau, Germany – October 21, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on its breakthrough moss technology platform, today announced that CPV-104, a recombinant human complement Factor H, has advanced into evaluation in patients with C3 glomerulopathy (C3G), a rare renal disease caused by dysregulation of the complement system. This follows the successful completion of the single ascending dose (SAD) part of its First in Human clinical trial investigating CPV-104 in 21 healthy volunteers. The study, designed to evaluate the safety, tolerability, and pharmacokinetics of CPV-104, included four dose cohorts and concluded with no safety concerns.
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteersFirst-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients
Eleva Appoints Donato Spota as Chief Financial OfficerFreiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer.
